Dynavax Technologies Corporation has received $-0.86 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 3 Financial Advisor in the Stock Trading Firms. Among 3 Analysts, Bottom line EPS Estimate for the current quarter is $-0.92 while the top line estimate is $-0.82 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -22.86%.
Dynavax Technologies Corporation results fell short with a surprise EPS of -11.11% or $-0.09. The Actual EPS was $-0.9 compared to the Estimated EPS of $-0.81 during its most recent quarterly earnings. Berkeley based Dynavax Technologies Corporation Last reported the Quarter results on Dec 31, 2016 and the Next earnings date is scheduled to be released on Mar 14, 2017.
In the last quarter, Dynavax Technologies Corporation reported Annual Earnings of $-0.9. Based on the filings, last years Annual Earnings was, $-3.25. In the last Quarter, DVAX reported a surprise Earnings per Share of -11.11% . The consensus estimate for current quarter is $-0.86 and for the current fiscal year, the estimate is $-3.21. For the Next fiscal year, the estimate is $-2.57 based on the consensus.
Dynavax Technologies Corporation (NASDAQ:DVAX) : On Tuesday heightened volatility was witnessed in Dynavax Technologies Corporation (NASDAQ:DVAX) which led to swings in the share price. The stock opened for trading at $3.85 and hit $4.125 on the upside , eventually ending the session at $4.1, with a gain of 6.49% or 0.25 points. The heightened volatility saw the trading volume jump to 1,475,435 shares. The 52-week high of the share price is $24.895 and the company has a market cap of $158 million. The 52-week low of the share price is at $3.2 .
Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavaxs clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.